The EU regulator is reviewing tralokinumab for the treatment of ... become a $10 billion brand at its peak. The drug’s mechanism of action simultaneously inhibits IL-4 and IL-13, which Sanofi ...

The drug is the first in over 30 years with a novel mechanism of action for treating schizophrenia ... and LEO Pharma's Adbry/Adtralza (tralokinumab). According to Clarivate, Ebglyss could become ...

Furthermore, we demonstrated that the learned compensatory mechanism contributing to associative morphine tolerance requires an action of CCK at the CCK-B receptor in the L/BL amygdala.

THE unravelling of the arrangement and complications of the nervous system has always been of great interest not only to physiologists, but also to mankind in general. The specially human ...